Literature DB >> 29138274

Five-Year Effectiveness of the Multidisciplinary Risk Assessment and Management Programme-Diabetes Mellitus (RAMP-DM) on Diabetes-Related Complications and Health Service Uses-A Population-Based and Propensity-Matched Cohort Study.

Eric Yuk Fai Wan1, Colman Siu Cheung Fung2, Fang Fang Jiao2, Esther Yee Tak Yu2, Weng Yee Chin2, Daniel Yee Tak Fong3, Carlos King Ho Wong2, Anca Ka Chun Chan2, Karina Hiu Yen Chan2, Ruby Lai Ping Kwok4, Cindy Lo Kuen Lam2.   

Abstract

OBJECTIVE: To evaluate the 5-year effectiveness of a multidisciplinary Risk Assessment and Management Programme-Diabetes Mellitus (RAMP-DM) in primary care patients with type 2 diabetes. RESEARCH DESIGN AND METHODS: A 5-year prospective cohort study was conducted with 121,584 Chinese primary care patients with type 2 DM who were recruited between August 2009 and June 2011. Missing data were dealt with multiple imputations. After excluding patients with prior diabetes mellitus (DM)-related complications and one-to-one propensity score matching on all patient characteristics, 26,718 RAMP-DM participants and 26,718 matched usual care patients were followed up for a median time of 4.5 years. The effect of RAMP-DM on nine DM-related complications and all-cause mortality were evaluated using Cox regressions. The first incidence for each event was used for all models. Health service use was analyzed using negative binomial regressions. Subgroup analyses on different patient characteristics were performed.
RESULTS: The cumulative incidence of all events (DM-related complications and all-cause mortality) was 23.2% in the RAMP-DM group and 43.6% in the usual care group. RAMP-DM led to significantly greater reductions in cardiovascular disease (CVD) risk by 56.6% (95% CI 54.5, 58.6), microvascular complications by 11.9% (95% CI 7.0, 16.6), mortality by 66.1% (95% CI 64.3, 67.9), specialist attendance by 35.0% (95% CI 33.6, 36.4), emergency attendance by 41.2% (95% CI 39.8, 42.5), and hospitalizations by 58.5% (95% CI 57.2, 59.7). Patients with low baseline CVD risks benefitted the most from RAMP-DM, which decreased CVD and mortality risk by 60.4% (95% CI 51.8, 67.5) and 83.6% (95% CI 79.3, 87.0), respectively.
CONCLUSIONS: This naturalistic study highlighted the importance of early optimal DM control and risk factor management by risk stratification and multidisciplinary, protocol-driven, chronic disease model care to delay disease progression and prevent complications.
© 2017 by the American Diabetes Association.

Entities:  

Mesh:

Year:  2017        PMID: 29138274     DOI: 10.2337/dc17-0426

Source DB:  PubMed          Journal:  Diabetes Care        ISSN: 0149-5992            Impact factor:   19.112


  22 in total

Review 1.  Quality of Diabetes Care in the USA.

Authors:  Ben Alencherry; Dennis Bruemmer
Journal:  Curr Cardiol Rep       Date:  2021-06-03       Impact factor: 2.931

2.  Cost-effectiveness of a primary care multidisciplinary Risk Assessment and Management Program for patients with diabetes mellitus (RAMP-DM) over lifetime.

Authors:  Fangfang Jiao; Eric Yuk Fai Wan; Colman Siu Cheung Fung; Anca Ka Chun Chan; Sarah Morag McGhee; Ruby Lai Ping Kwok; Cindy Lo Kuen Lam
Journal:  Endocrine       Date:  2018-08-28       Impact factor: 3.633

Review 3.  Chronic Care Management Services for Complex Diabetes Management: a Practical Overview.

Authors:  Kayla L Del Valle; Marie E McDonnell
Journal:  Curr Diab Rep       Date:  2018-10-20       Impact factor: 4.810

4.  Secular trends in all-cause and cause-specific mortality rates in people with diabetes in Hong Kong, 2001-2016: a retrospective cohort study.

Authors:  Hongjiang Wu; Eric S H Lau; Ronald C W Ma; Alice P S Kong; Sarah H Wild; William Goggins; Elaine Chow; Wing-Yee So; Juliana C N Chan; Andrea O Y Luk
Journal:  Diabetologia       Date:  2020-01-16       Impact factor: 10.122

5.  2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.

Authors:  Donna K Arnett; Roger S Blumenthal; Michelle A Albert; Andrew B Buroker; Zachary D Goldberger; Ellen J Hahn; Cheryl Dennison Himmelfarb; Amit Khera; Donald Lloyd-Jones; J William McEvoy; Erin D Michos; Michael D Miedema; Daniel Muñoz; Sidney C Smith; Salim S Virani; Kim A Williams; Joseph Yeboah; Boback Ziaeian
Journal:  J Am Coll Cardiol       Date:  2019-03-17       Impact factor: 24.094

6.  2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.

Authors:  Donna K Arnett; Roger S Blumenthal; Michelle A Albert; Andrew B Buroker; Zachary D Goldberger; Ellen J Hahn; Cheryl Dennison Himmelfarb; Amit Khera; Donald Lloyd-Jones; J William McEvoy; Erin D Michos; Michael D Miedema; Daniel Muñoz; Sidney C Smith; Salim S Virani; Kim A Williams; Joseph Yeboah; Boback Ziaeian
Journal:  J Am Coll Cardiol       Date:  2019-03-17       Impact factor: 24.094

Review 7.  2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.

Authors:  Donna K Arnett; Roger S Blumenthal; Michelle A Albert; Andrew B Buroker; Zachary D Goldberger; Ellen J Hahn; Cheryl Dennison Himmelfarb; Amit Khera; Donald Lloyd-Jones; J William McEvoy; Erin D Michos; Michael D Miedema; Daniel Muñoz; Sidney C Smith; Salim S Virani; Kim A Williams; Joseph Yeboah; Boback Ziaeian
Journal:  Circulation       Date:  2019-03-17       Impact factor: 29.690

Review 8.  2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.

Authors:  Donna K Arnett; Roger S Blumenthal; Michelle A Albert; Andrew B Buroker; Zachary D Goldberger; Ellen J Hahn; Cheryl Dennison Himmelfarb; Amit Khera; Donald Lloyd-Jones; J William McEvoy; Erin D Michos; Michael D Miedema; Daniel Muñoz; Sidney C Smith; Salim S Virani; Kim A Williams; Joseph Yeboah; Boback Ziaeian
Journal:  Circulation       Date:  2019-03-17       Impact factor: 29.690

Review 9.  Evolution of Diabetes Care in Hong Kong: From the Hong Kong Diabetes Register to JADE-PEARL Program to RAMP and PEP Program.

Authors:  Ivy H Y Ng; Kitty K T Cheung; Tiffany T L Yau; Elaine Chow; Risa Ozaki; Juliana C N Chan
Journal:  Endocrinol Metab (Seoul)       Date:  2018-03

10.  Trends in kidney failure and kidney replacement therapy in people with diabetes in Hong Kong, 2002-2015: A retrospective cohort study.

Authors:  Hongjiang Wu; Eric S H Lau; Aimin Yang; Cheuk-Chun Szeto; Ronald C W Ma; Alice P S Kong; Elaine Chow; Wing-Yee So; Juliana C N Chan; Andrea O Y Luk
Journal:  Lancet Reg Health West Pac       Date:  2021-06-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.